期刊文献+

草酸铂联合方案治疗晚期复治胃肠道癌的临床观察 被引量:2

Oxaliplatin combined with fluorouracil and calaium folinate in the treatment of patients with advanced and pretreated gastroinstestinal cancer
下载PDF
导出
摘要 目的 :研究奥沙利铂 (L- OHP)与氟尿嘧啶 (5 - Fu)、甲酰四氢叶酸钙 (CF)联合方案治疗晚期并含 5 - Fu方案化疗失败的胃癌和大肠癌的疗效和毒副反应。方法 :L- OHP35 mg/ m2 ,静脉滴注 4 h,d1~ d4 ;5 - FU 5 0 0 mg/ m2 ,静脉滴注 4 h(接 L-OHP) ,d1~ d4 ;CF10 0 mg/ m2 ,静脉滴注 4 h(5 - Fu与 CF从 Y型管同时滴注 ) ,d1~ d4 ,2 1或 2 8天为 1周期。结果 :共治疗 2 2例患者 ,CR1例 ,PR6例 ,SD8例 ,PD7例 ,有效率为 31.8%。各病种的疗效为 :胃癌 2 / 4例 ,大肠癌 2 7.8% (5 / 18)。中位有效缓解期为4个月 (范围 2~ 7个月 )。有 5 4 .5 % (12 / 2 2 )患者在治疗后原有的临床症状有不同程度的改善。主要不良反应为贫血、白细胞和血小板减少、恶心呕吐、口腔炎及末梢神经炎 ,多为 1~ 2度。结论 :奥沙利铂与 5 - Fu、CF联合应用治疗晚期、复治的胃肠道癌疗效确切 。 Objective:To study the response and toxicity of the regimen of oxaliplatin (L OHP) combined with fluorouracil(5 Fu) and calcium folinate(CF)in the treatment of advanced and pretreated gastrointestinal cancer Methods:22 cases with advanced,failed previous 5 Fu based chemotherapy gastrointestinal cancer (including 4 patients with gastric cancer and 18 patients with colorectal cancer)were treated with:L OHP 35mg/m 2 iv infusion for 4 h D1 to D4,followed by 5 Fu 500mg/m 2 for 4h D1 to D4,and CF 100mg/m 2 for 4h D1 to D4(5 Fu and CF were infused at the same time),repeated every 3 or 4 weeks Results:The total response rate was 31 8%,the main side effects were bone marrow suppression,nausea and vomiting,oral mucositis and peripheral sensory neuropathy.The whole toxicity was mild and tolerable Conclusion:The regimen of L OHP combined with 5 Fu/CF was effective and well tolerable in the treament of patients with advanced and pretreated gastrointestinal cancer
出处 《广西医学》 CAS 2003年第10期1875-1877,共3页 Guangxi Medical Journal
关键词 胃肠道癌 草酸铂 奥沙利铂 5-氟尿嘧啶 甲酰四氢叶酸钙 化学治疗 Gastrc cancer Colorectal cancer Oxaliplatin Fuorouracil(5 FU) Calcium folinate(CF)
  • 相关文献

参考文献8

二级参考文献20

  • 1周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,1997,1.417.
  • 2李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 3孙燕,临床肿瘤内科手术 第3版(第3版),1996年,33-101,214-215页
  • 4Jennerwein MM,Eastman A,Khokhar A.Characterizotion of adduct produced in DNA by isomeric 1,2-diaminocyclohexane platinum(Ⅱ)complexes[J].Chem Biol Interact,1989,70(1-2);39-49.
  • 5Kraker AJ,Moore CW.Accumulation of cis-diamminedichloroplatinum(Ⅱ) and platinum analogues by platinum-resistant murine leukemia cells in vitro[J].Cancer Res,1988,48(1):9-13.
  • 6Tashiro T,Kowada Y,Sakuria Y,et al.Autitumor activity of a new platinum complexe,oxalato(trains-1-1,2-diamminedichexane) platinum(Ⅱ):new experimental data[J]. Biomed Pharmacother,1989,43(4):251-260.
  • 7Diaz-Rubio E, Ssatre J, Zaniboni A.Oxaliplatin as single agent in previously untreated colorectal carcinoma patients:a phase Ⅱ multicentric study [J].Ann Oncol,1998,9:105-108.
  • 8Becouarn Y,Ychou M,Ducreux M,et al.PhaseⅡtrail of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers[J]. J Clin Oncol,1998,16(8):2739-2744.
  • 9Ducreux M, Louvet C, Bekradda M, et al. Oxaliplatin for the treatment of advanced colorectal cancer: future directions [J].Semin Oncol,1998,25(2 Suppl 5):47-53.
  • 10Raymond E, Faivre S, Woynarowski JM, et al.Oxasliplatin:mechanism of action and antineoplastic activity[J]. Semin Oncol,1998,25(2:Suppl 5):4-12.

共引文献355

同被引文献9

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部